CryoPort (NASDAQ:CYRX) Hits New 52-Week High – Should You Buy?

CryoPort, Inc. (NASDAQ:CYRX)’s stock price reached a new 52-week high on Wednesday . The stock traded as high as $13.79 and last traded at $13.8010, with a volume of 113845 shares trading hands. The stock had previously closed at $13.03.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on CYRX shares. Weiss Ratings upgraded shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. Wall Street Zen upgraded shares of CryoPort from a “sell” rating to a “hold” rating in a report on Monday, May 11th. KeyCorp raised their target price on shares of CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday. Guggenheim raised their target price on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Needham & Company LLC raised their target price on shares of CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.69.

CryoPort Stock Up 4.8%

The firm has a market capitalization of $688.24 million, a PE ratio of 10.09 and a beta of 1.75. The business’s fifty day moving average price is $9.94 and its 200 day moving average price is $9.55.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The firm had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $44.86 million. CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%. As a group, sell-side analysts forecast that CryoPort, Inc. will post -0.74 earnings per share for the current fiscal year.

Insider Transactions at CryoPort

In related news, CEO Jerrell Shelton sold 7,918 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $63,344.00. Following the sale, the chief executive officer directly owned 1,054,501 shares of the company’s stock, valued at approximately $8,436,008. This trade represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark W. Sawicki sold 3,235 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $25,880.00. Following the completion of the sale, the insider directly owned 103,697 shares in the company, valued at $829,576. This represents a 3.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 59,939 shares of company stock worth $471,183 over the last ninety days. 10.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CryoPort

Hedge funds have recently modified their holdings of the stock. Basepoint Wealth LLC acquired a new stake in shares of CryoPort in the fourth quarter worth approximately $34,000. Tower Research Capital LLC TRC boosted its position in shares of CryoPort by 300.1% in the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after acquiring an additional 4,375 shares during the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of CryoPort in the third quarter worth approximately $53,000. AlphaQuest LLC acquired a new stake in shares of CryoPort in the third quarter worth approximately $79,000. Finally, Creative Planning acquired a new stake in shares of CryoPort in the second quarter worth approximately $96,000. 92.90% of the stock is owned by institutional investors and hedge funds.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.